Tuesday, April 23, 2024

Upperton joined by Oxford/AstraZeneca COVID-19 vaccine co-inventor to open new development and GMP manufacturing facility

Contract development and manufacturing organisation (CDMO) Upperton Pharma Solutions was joined by Oxford/AstraZeneca COVID-19 vaccine co-inventor Professor Dame Sarah Gilbert, biotech industry representatives and local leaders to celebrate the official opening of a new 50,000 square foot development and GMP manufacturing facility in Nottingham.

In addition to Professor Dame Sarah Gilbert, the plaque-unveiling ceremony included local Member of Parliament, Darren Henry MP, and leading industry professionals.

Nikki Whitfield, CEO of Upperton Pharma Solutions, said: “This celebration marks another milestone in our incredible growth journey as a business. We are looking forward to officially opening our doors to customers and offering a single site solution for development and GMP manufacturing.”

“It was a pleasure to join Upperton for the grand opening of their new facility,” said Guest of Honour, Professor Dame Sarah Gilbert, Principal Investigator at the Pandemic Sciences Institute, University of Oxford and co-creator of the Oxford/AstraZeneca COVID-19 vaccine.

“During the pandemic we saw the importance of academia and industry working closely together to deliver life-saving vaccines and treatments. Upperton’s expansion into this new site is a great example of the crucial role UK-based pharmaceutical organisations have to play in addressing global health challenges. I look forward to collaborating with Upperton in the future.”

The new facility contains ten GMP manufacturing suites, cutting-edge quality control laboratories, and formulation development capabilities equipped with a pilot plant. The facility empowers Upperton to offer customers a seamless transition from early formulation development to clinical trial supplies from Phase 1 to Phase 3 and niche scale commercial manufacturing all on one site.

The official opening marks another milestone for Upperton following the announcement and ongoing build of a new sterile facility on the same site, for the manufacturing of aseptic and terminally sterilized small volume liquids for parenteral, ocular and pulmonary delivery due for completion at the end of 2024.

A message from the Editor:

Thank you for reading this story on our news site - please take a moment to read this important message:

As you know, our aim is to bring you, the reader, an editorially led news site and magazine but journalism costs money and we rely on advertising, print and digital revenues to help to support them.

With the Covid-19 pandemic having a major impact on our industry as a whole, the advertising revenues we normally receive, which helps us cover the cost of our journalists and this website, have been drastically affected.

As such we need your help. If you can support our news sites/magazines with either a small donation of even £1, or a subscription to our magazine, which costs just £33.60 per year, (inc p&P and mailed direct to your door) your generosity will help us weather the storm and continue in our quest to deliver quality journalism.

As a subscriber, you will have unlimited access to our web site and magazine. You'll also be offered VIP invitations to our events, preferential rates to all our awards and get access to exclusive newsletters and content.

Just click here to subscribe and in the meantime may I wish you the very best.

Latest news

Related news

By continuing to use the site, you agree to the use of cookies. more information

The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.